INVESTOR RELATIONS

Stock price

NYSEVAR

$3.2B
FY 2019 REVENUES
10%
REVENUES GROWTH IN FY 2019
9%
ONCOLOGY ORDERS GROWTH IN FY 2019
5%
NON-GAAP EPS ¹ GROWTH IN FY 2019

$3.2B
FY 2019 REVENUES
10%
REVENUES GROWTH IN FY 2019
9%
ONCOLOGY ORDERS GROWTH IN FY 2019
5%
NON-GAAP EPS ¹ GROWTH IN FY 2019

Press Releases

Mar 17, 2020

Alabama's Only Proton Therapy Center Treats First Patient with Varian ProBeam

Varian (NYSE: VAR) announced today, Proton International at UAB has now treated its first cancer patient with the Varian ProBeam® Compact proton therapy system. The center, a collaboration...

Mar 16, 2020

Varian to Equip New Ethos Personalized Adaptive Therapy Center in Phoenix

Varian (NYSE: VAR) today announced it was selected to equip the new Ethos Personalized Adaptive Therapy Center in Phoenix, Arizona, and help launch a new era in cancer treatment for patients in...

Mar 16, 2020

Varian Halcyon 2.0 Treatment System Receives China NMPA Approval

Varian (NYSE: VAR) today announced its Halcyon™ 2.0 treatment system has been approved by the China National Medical Products Administration (NMPA), which allows the company to market this...

Mar 11, 2020

Quebec Selects Varian to Increase Access to Advanced Cancer Care

Varian (NYSE: VAR) today announced that the procurement representative of the Quebec government, Groupe d'Approvisionnement Commun de l'Est du Québec (GACEQ), filed a notice of intent to award a...

View all press releases

Upcoming Events

No events to display

View all events

Past Events

BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Wednesday, March 18, 2020

Barclays Global Healthcare Conference

Tuesday, March 10, 2020

8:00am EDT

Varian to Discuss Expected Impact from COVID-19

Monday, March 9, 2020